Piclozotan

Piclozotan

Piclozotan
Systematic (IUPAC) name
3-chloro-4-[4-[4-(2-pyridinyl)-1,2,3,6-tetrahydropyridin-1-yl]butyl]-1,4-benzoxazepin-5(4H)-one
Clinical data
Legal status
  • Uncontrolled
Identifiers
CAS number  YesY
ATC code ?
PubChem
ChemSpider  N
UNII  YesY
Chemical data
Formula C23H24ClN3O2 
Mol. mass 409.909 g/mol
 N   

Piclozotan (SUN-N4057) is a selective 5-HT1A receptor partial agonist, which has neuroprotective effects in animal studies.[1] It has been through early clinical trials in humans for treatment of acute stroke, but results have not yet been announced.[2][3]

See also

References

  1. ^ Kamei, K.; Maeda, N.; Nomura, K.; Shibata, M.; Katsuragi-Ogino, R.; Koyama, M.; Nakajima, M.; Inoue, T.; Ohno, T.; Tatsuoka, T. (2006). "Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan". Bioorganic & Medicinal Chemistry 14 (6): 1978–1992.  
  2. ^ Ferro, J.; Dávalos, A. (2006). "Other neuroprotective therapies on trial in acute stroke". Cerebrovascular diseases (Basel, Switzerland). 21 Suppl 2 (2): 127–130.  
  3. ^ Mondick, J.; Oo, C.; Patel, D.; Fujitani, T.; Shimizu, K.; Barrett, J. (2009). "Population pharmacokinetics of the selective serotonin 5-HT1A receptor partial agonist piclozotan". American journal of therapeutics 16 (2): 106–115.